Purdue Pharma L.P. and AnaBios Corporation announced today the intent to
form a joint venture aimed at accelerating the development of Purdue
Pharma’s Nav1.7 sodium ion channel compounds for the treatment of
chronic pain. The joint research and development effort would leverage
Purdue Pharma’s intellectual property and lead compounds, combined with
AnaBios’ Phase-X® technology.
Purdue Pharma has more than 10 years of research history in the
sodium channel field that led to multiple patent applications and
numerous lead compounds targeting Nav1.7 as well as other sodium channel
isoforms that are potentially useful for the treatment of chronic pain.
Purdue Pharma also has extensive clinical development experience in
advancing new drugs for treating pain
AnaBios is an innovative drug discovery company employing its proprietary Phase-X®
technology to enable the discovery of novel drugs directly in human
tissues, bypassing animal experimentation. AnaBios generates highly
valuable and predictive human data that ensure the selection of the most
effective and safest drugs before investing in expensive and time
consuming clinical trials. AnaBios has established a unique and
unprecedented capability for studying the human peripheral pain pathway
in the laboratory, therefore enabling the identification of novel
analgesic drugs with potential efficacy in human.
